Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Allogene Therapeutics has announced promising data from the Phase 1 UNIVERSAL study of ALLO-715 for relapsed/refractory multiple myeloma. As of October 30, 2020, the study involved 35 patients, with 31 evaluable for safety and 26 for efficacy. The study reported a 60% overall response rate and a 40% very good partial response rate, with no instances of graft-versus-host disease or severe neurotoxicity observed. The data highlight the potential of ALLO-715 as an effective off-the-shelf therapy with fast treatment initiation, supporting its continued development and trials in the future.

Allogene Therapeutics (ALLO) is set to review initial results from the ALLO-715 UNIVERSAL Phase 1 trial targeting relapsed/refractory multiple myeloma in a live webinar scheduled for December 5, 2020, at 11:00 AM PT/2:00 PM ET. The webinar will feature key executives including CEO David Chang and CMO Rafael Amado. This clinical-stage biotechnology firm focuses on developing allogeneic CAR T therapies, aiming to provide scalable, readily available cancer treatments. Registration for the webinar is available on the company's website.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced its participation in four upcoming investor conferences, aiming to enhance investor relations. The conferences include the Stifel 2020 Virtual Healthcare Conference on November 16, Jefferies Virtual London Healthcare Conference on November 17, Piper Sandler’s 32nd Annual Virtual Healthcare Conference on December 2, and the JMP Securities Hematology Summit on December 15. Presentations will be webcasted and available on the company's website for 30 days post-event, promoting transparency and engagement with stakeholders.

Allogene Therapeutics announced promising initial results from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T therapy for relapsed/refractory multiple myeloma. The therapy demonstrated a 60% overall response rate (ORR) at the highest administered dose of 320M CAR+ cells, with all responding patients achieving minimal residual disease (MRD) negative status. Notably, there was no observed neurotoxicity or graft-vs-host disease (GvHD). Ongoing enrollment aims to optimize dosing and lymphodepletion, with further data to be presented at the upcoming ASH Annual Meeting.

Allogene Therapeutics (ALLO) provided a corporate update and reported Q3 2020 financial results, reflecting continued progress in developing its AlloCAR T therapies. The company ended Q3 with $1.0 billion in cash and expects to submit several Investigational New Drug applications, including for ALLO-316 and ALLO-715, by the end of 2020. Initial clinical data from the UNIVERSAL trial for ALLO-715 in multiple myeloma will be announced in Q4 2020. Full-year net losses are projected between $260 million and $280 million, including significant stock-based compensation.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) will announce its Q3 2020 financial results on November 4, 2020, prior to market opening. A conference call and audio webcast will follow at 5:30 AM PT / 8:30 AM ET. The company focuses on developing allogeneic CAR T cell therapies, aiming to provide readily available treatment options for cancer patients. A replay of the webcast will be available for 30 days on their website. The press release contains forward-looking statements about the company's future and the potential benefits of its therapies.

Allogene Therapeutics (Nasdaq: ALLO) has entered a five-year collaboration with The University of Texas MD Anderson Cancer Center to evaluate multiple AlloCAR T candidates targeting various tumors. This partnership aims to expedite the development of allogeneic CAR T therapies, leveraging MD Anderson's clinical trial expertise and Allogene's cell therapy knowledge. The collaboration will entail joint oversight of preclinical and clinical studies, with Allogene funding the initiative.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotech firm, announced its participation in the Jefferies Virtual Cell Therapy Summit on October 6, 2020. The event is scheduled for 12:30 PM PT/3:30 PM ET and will focus on the development of allogeneic CAR T therapies for cancer. A live webcast will be available on the company's website, with a replay for 30 days. Allogene aims to provide 'off-the-shelf' CAR T therapies, enhancing patient access and scalability in treatment.

Allogene Therapeutics reported promising initial Phase 1 results from the ALLO-501 ALPHA trial, showcasing a 75% overall response rate and 44% complete response rate in CAR T naïve relapsed/refractory non-Hodgkin lymphoma patients. Ongoing trials for ALLO-501A and ALLO-715 are also being developed, with initial data expected in Q4 2020. The company reported a net loss of $61.0 million for Q2 2020, while ending the quarter with $1.1 billion in cash and equivalents, ensuring robust financial support for upcoming clinical trials.